Pular para o conteúdo principal
Ranking Invest

TERN - Terns Pharmaceuticals, Inc.

Segmento: HealthcareTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Análise Ranking Invest

Valuation estimado
$ 62.14 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 326.04 Mi

Dívida Líquida

-$ 137.79 Mi

L4T

-$ 90.39 Mi

Indicadores Básicos

ROE

-27.72%

Índices de Previsibilidade

Receita Líquida

G1.29

Lucro

A0.09

Margem

E1.73

Índices de Tendência

Receita Líquida

E-3.96

Lucro

G-9.83

Margem

D1.26

Índices de Endividamento

DIV/PAT

-0.42

DIV/L4T

1.52

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.